The decision comes even though a pivotal confirmatory study failed to demonstrate significant improvements in motor function, a result that would typically raise concerns about conversion from accelerated to full approval.

FDA Review Moves Forward After ESSENCE Trial Results

Amondys 45 and Vyondys 53 are exon-skipping therapies designed for specific genetic subtypes of DMD. The drugs received accelerated approvals in 2021 and 2019, respectively, based largely on their ability to increase dystrophin production, a biomarker considered reasonably likely to predict clinical benefit.

However, the Phase 3 ESSENCE trial, conducted to confirm clinical benefit, reported in late 2024 that neither treatment achieved statistically significant improvements in motor function compared with placebo. Despite these findings, the FDA has agreed to review Sarepta’s applications for conventional approval.

In addition to data from the clinical program, Sarepta’s submission includes published real-world evidence and extensive safety information gathered since the products entered the market.

Real-World Evidence May Influence Regulatory Assessment

Industry analysts view the FDA’s acceptance of the filings as potentially encouraging for Sarepta. According to analysts from Oppenheimer, the inclusion of additional real-world data and consistent safety findings could strengthen the company’s case, particularly given the importance regulators often place on long-term safety in rare disease treatments.

Analysts at Jefferies highlighted observational evidence suggesting that patients receiving the exon-skipping therapies may experience benefits such as prolonged ambulation, reduced dependence on ventilatory support, and fewer hospital visits. They noted that adverse events associated with the therapies have generally been mild to moderate, contributing to a potentially favorable benefit-risk profile.

Because DMD is a progressive and fatal neuromuscular disorder with limited treatment options, regulators may weigh broader measures of patient outcomes alongside traditional clinical trial endpoints.

Changing Regulatory Environment Raises Questions

Some observers believe evolving dynamics within the FDA could also influence the review process. Recent discussions in the biotechnology sector have focused on whether the agency may become more receptive to alternative forms of evidence in rare diseases, particularly when conventional clinical trials are difficult to conduct.

Analysts have pointed to several recent examples in which the FDA has reconsidered prior positions or agreed to review submissions supported by nontraditional datasets. These developments have fueled speculation that regulators may be increasingly willing to consider real-world or externally controlled evidence when evaluating therapies for rare conditions.

Potential Win for Sarepta Amid Recent Challenges

A favorable decision on Amondys 45 and Vyondys 53 would represent a significant victory for Sarepta following a difficult period for the company.

Over the past year, scrutiny has intensified following patient deaths associated with the company’s gene therapy programs. Sarepta’s approved DMD gene therapy, Elevidys, was linked to two reported patient deaths in 2025, while another fatality occurred in a patient treated with an investigational gene therapy for limb-girdle muscular dystrophy.

In response to these events, the biotechnology company has shifted strategic emphasis away from gene therapy development and toward RNA-targeting approaches, including RNA interference technologies.

Looking Ahead

The FDA’s review of Amondys 45 and Vyondys 53 will be closely watched across the neuromuscular disease community. The agency’s eventual decision could provide insight into how regulators balance negative confirmatory trial results against long-term safety findings and real-world evidence in rare diseases.

With a decision expected by early 2027, the outcome may also help shape future regulatory pathways for therapies developed under the accelerated approval framework, particularly in conditions where large, definitive clinical studies remain challenging to conduct.